Moderna, Inc.'s stock surged 8.85% during early trading on Thursday, driven by multiple positive developments that converged to boost investor confidence.

The primary catalyst stems from significant progress in the FDA's review of Moderna's mRNA flu vaccine candidate, mFlusiva. The regulatory agency's advisory committee is set to vote on whether the vaccine's benefits outweigh risks for elderly populations. If approved, mFlusiva would become the first mRNA-based seasonal flu vaccine available in the United States, offering faster production capabilities compared to traditional egg-based methods.

Additionally, Moderna has completed an organizational restructuring, appointing Ester Banque as Chief Commercial Officer to prepare for potential launches of up to three new vaccines over the next two years. The company is also evaluating investments in production facilities in Germany to expand its manufacturing capacity for the European market, further supporting its growth trajectory.